01/11/2026
The confusion surrounding exosomes in the Canadian market intensified following Health Canada’s April 2025 advisory notice, which had a significant impact on the aesthetic industry and prompted widespread requests for clarification. In the notice, Health Canada stated that human-derived exosomes were under further investigation and were being removed from the market due to their classification as a drug. This created uncertainty among providers, particularly nurses, who must clearly understand how exosomes are regulated in Canada to protect their licence, safeguard their clinic, and avoid unnecessary regulatory or compliance risks.
Read the complete blog on THMA Patreon through the link below.
https://www.patreon.com/posts/confusion-in-147958321?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=postshare_creator&utm_content=join_link